Pfizer makes dramatic cut to US sales force
Pfizer is reorganising its US sales organisation - over 2000 jobs will be cut, and wider cuts may follow.
Pfizer is reorganising its US sales organisation - over 2000 jobs will be cut, and wider cuts may follow.
The cuts reduce the US sales organisation by pproximately 20%. The company emphasised that sales forces for brands Lipitor, Celebrex and Geodon, as well as new products such as Lyrica, Exubera, Chantix and Sutent were to be least affected by the cuts.
Pfizer announced in mid-October that it would undertake a companywide review aimed at creating efficiencies and, in January, it will present its long-term outlook with additional actions for transforming the company.
"This is an important step toward making Pfizer a more agile and effective company," said Jeffrey Kindler, Pfizer's ceo.
Ian Read, president of Pfizer Worldwide Pharmaceutical Operations, said, "The US sales organisation has done an outstanding job this year. At the same time, it is incumbent upon us to look ahead and carefully assess our changing marketplace and all the factors affecting our outlook, so that we can align our organisation to properly support our key products and customer needs."